Retroviral Proteases: A Potential Target for Development of Antiviral Agents

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Trends in Biotechnology and Pharmacy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Topological models for the prediction of HIV-protease inhibitory activity of tetrahydropyrimidin-2-ones.

  2005cited by this paper
• De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule.

  2002cited by this paper
• Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.

  2002cited by this paper
• Retroviral proteases

  2002cited by this paper
• Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.

  2000cited by this paper
• Structural and biochemical studies of retroviral proteases.

  2000cited by this paper
• Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.

  1998cited by this paper
• HIV protease inhibitors

  1996cited by this paper
• Structure of equine infectious anemia virus proteinase complexed with an inhibitor

  1996cited by this paper
• Perspectives in HIV protease inhibitors.

  1996cited by this paper
• Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

  1996cited by this paper
• ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

  1995cited by this paper
• Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus

  1995cited by this paper
• HIV protease as an inhibitor target for the treatment of AIDS.

  1994cited by this paper
• Design of tight-binding human immunodeficiency virus type 1 protease inhibitors.

  1994cited by this paper
• HIV protease inhibitors: their anti-HIV activity and potential role in treatment.

  1993cited by this paper
• Structure of the protease from simian immunodeficiency virus: complex with an irreversible nonpeptide inhibitor.

  1993cited by this paper
• A consensus template for the aspartic proteinase fold.

  1991cited by this paper
• Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase.

  1991cited by this paper
• Translational suppression in gene expression in retroviruses and retrotransposons.

  1990cited by this paper
• Comparison of inhibitor binding in HIV‐1 protease and in non‐viral aspartic proteases: the role of the flap

  1990cited by this paper
• A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.

  1990cited by this paper
• Crystal structure of a retroviral protease proves relationship to aspartic protease family

  1989cited by this paper
• Cleavage of HIV-1 gag Polyprotein Synthesized In Vitro: Sequential Cleavage by the Viral Protease

  1989cited by this paper
• Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.

  1989cited by this paper
• Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

  1989cited by this paper
• Active human immunodeficiency virus protease is required for viral infectivity.

  1988cited by this paper
• Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

  1988cited by this paper

• Impact of L38↑N↑L insertions on structure and function of HIV-1 South African subtype C Protease

  2012cites this paper